Independent fund research. Built on SEC filings.

How we research funds

ETF · Leveraged & Inverse · Direxion

Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU)

Ticker TBXU · · Holdings as of Jul 31, 2026

Expense ratio
0.98%$98/yr per $10k
Net assets
$2.6Mall share classes
Holdings
10

Bottom line

Is TBXU a good fund? The bottom line

TBXU is a managed leveraged & inverse ETF from Direxion.

Annual fees run 0.98% — about $98 a year on every $10,000 invested, cheaper than 76% of leveraged & inverse funds we track.

With $2.6 million in net assets and 10 holdings, its largest position is Goldman Financial (29.4%) and the top 10 make up 100.1% of the portfolio.

What stands out

  • Low cost: cheaper than 76% of leveraged & inverse peers

What to watch

  • Concentrated: top 10 holdings are 100.1% of assets
  • Small fund ($2.6 million) — small funds are likelier to close

Updated Nov 19, 2026

What TBXU invests in

The Fund seeks daily investment results, before fees and expenses, of 200% of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.

"The Index consists of the top five securities in the NYSE Biotechnology Index, which includes U.S.-listed companies in the biotechnology sub-industry as classified by the Global Industry Classification Standards (GICS). ICE Data Indices, LLC (the Index Provider) selects the top five securities of the NYSE Biotechnology Index based on each securitys total market capitalization. The Index is equal weighted, meaning that at each rebalancing of the Index, the same exposure is provided to each security included in the Index. The Index is rebalanced and reconstituted quarterly. As of December 31, 2025, the Index had five constituents, which were concentrated in the biotechnology industry, which is part of the healthcare sector. The Fund, under normal circumstances, invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments, securities of the…

From the fund's prospectus (filed Mar 3, 2026).

What TBXU costs

On a $10,000 investment, TBXU's 0.98% expense ratio costs about $98 a year. The prospectus estimates $5,645 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.

See the full TBXU fee table →

TBXU top 10 holdings

#Holding% of fund
1Goldman Financial29.36%
2Dreyfus21.64%
3Regeneron Pharmaceuticals Inc REGN9.09%
4Amgen Inc AMGN7.95%
5Vertex Pharmaceuticals Inc VRTX7.84%
6Gilead Sciences Inc GILD7.58%
7Argenx Se - Adr ARGX6.98%
8Goldman Sachs Liq Es Fd A6.23%
9N/a2.83%
10N/a0.62%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 100.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to TBXU

More funds like TBXU →

TBXU FAQ

What is the expense ratio of TBXU?
TBXU's expense ratio is 0.98%, which works out to about $98 a year for every $10,000 invested. The prospectus estimates total costs of $5,645 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is TBXU a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 76% of leveraged & inverse peers; concentrated: top 10 holdings are 100.1% of assets; small fund ($2.6 million) — small funds are likelier to close. This is general information, not personalized advice.
What does TBXU hold?
TBXU's largest holdings are Goldman Financial (29.4%), Dreyfus (21.6%), Regeneron Pharmaceuticals Inc (9.1%), Amgen Inc (7.9%), Vertex Pharmaceuticals Inc (7.8%). It holds 10 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
Who manages TBXU?
TBXU is offered by Direxion through Direxion Shares ETF Trust.